KYMR · Kymera Therapeutics Inc
United States · RS rating 97 · As of 2026-11-03
| Price | 127.09 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 97 / 90 / 90 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 49 / 57 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -3.2% |
| Sales growth Q/Q | +3.8% |
| Distance from 52-week high | +0.3% |
| Market cap (USD) | $7.1B |